Lonza Group AG (FRA:LO3)

Revenue

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2018 - 2020
Integrated Biologics Revenue	3.78B	3.68B	Log In	Log In	Log In	Upgrade
Advanced Synthesis Revenue	1.26B	983.00M	Log In	Log In	Log In	Upgrade
Specialized Modalities Revenue	832.00M	689.00M	Log In	Log In	Log In	Upgrade
Capsules & Health Ingredients Revenue	1.04B	1.05B	Log In	Log In	Log In	Upgrade
Corporate Revenue	186.00M	172.00M	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2018 - 2020
Europe Revenue	3.14B	Log In	Log In	Log In	Upgrade
North and Central America Revenue	2.44B	Log In	Log In	Log In	Upgrade
Latin America Revenue	129.00M	Log In	Log In	Log In	Upgrade
Asia Revenue	837.00M	Log In	Log In	Log In	Upgrade
Australia & New Zealand Revenue	17.00M	Log In	Log In	Log In	Upgrade
Other Geographic Revenue	3.00M	Log In	Log In	Log In	Upgrade

Adjusted EBITDA

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2018 - 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2018 - 2020
Integrated Biologics Core EBITDA	1.33B	1.27B	Log In	Log In	Log In	Upgrade
Advanced Synthesis Core EBITDA	489.00M	351.00M	Log In	Log In	Log In	Upgrade
Specialized Modalities Core EBITDA	128.00M	108.00M	Log In	Log In	Log In	Upgrade
Capsules & Health Ingredients Core EBITDA	259.00M	256.00M	Log In	Log In	Log In	Upgrade
Corporate Core EBITDA	-127.00M	-73.00M	Log In	Log In	Log In	Upgrade

Updated Jun 30, 2025. Data Source: Fiscal.ai.